<![CDATA[BI-1808 Earns FDA Fast Track Status for Advanced Ovarian Cancer]]>

RegulatoryBI-1808pembrolizumabPositive

AI Analysis

Summary

BI-1808 in combination with pembrolizumab received FDA fast track designation for advanced platinum-resistant ovarian cancer, demonstrating a 24% confirmed objective response rate in pretreated patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

FDA granted fast track designation

Importance:7/10

Sentiment:

0.70

FDA Fast TrackOvarian CancerImmunotherapyORR Data

Read the original article

Published by Cancer Network on August 10, 2026 3:00 PM

Read Original